Isocarboxazid

From Wikipedia, the free encyclopedia

Isocarboxazid chemical structure
Isocarboxazid
Systematic (IUPAC) name
N'-benzyl-5-methyl-oxazole-3-carbohydrazide
Identifiers
CAS number 59-63-2
ATC code N06AF01
PubChem 3759
DrugBank APRD00701
Chemical data
Formula C12H13N3O2 
Mol. weight 231.26
Pharmacokinetic data
Bioavailability  ?
Metabolism Liver
Half life  ?
Excretion Urine
Therapeutic considerations
Pregnancy cat.

C (USA)

Legal status

Prescription only

Routes Oral

Isocarboxazid is a nonselective hydrazine-derived monoamine oxidase inhibitor used in treatment resistant depression.

Contents

[edit] Uses

[edit] Approved

In the United States, isocarboxazid is approved for the treatment of depression.

In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs).

[edit] Off-Label/Unapproved/Investigational

A randomized controlled trial published in December of 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.[1]

[edit] Brand Names

[edit] United States

MARPLAN® by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough Marplan® to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product Marplan® (isocarboxazid) from Roche."[2]

The maximum daily dose of isocarboxazid is 60mg.

[edit] United Kingdom

Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF).


[edit] References

  1.   Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. "A trial of isocarboxazid in the treatment of bulimia nervosa." Journal of Clinical Psychopharmacology. 1988 Dec;8(6):391-6. PMID 3069879
  2.   Marplan Press Release Oxford Pharmaceutical Services.


Antidepressants (ATC N06A) edit
Monoamine oxidase inhibitors (MAOI) Harmaline, Iproclozide, Iproniazid, Isocarboxazid, Nialamide, Phenelzine, Selegiline, Toloxatone, Tranylcypromine
Reversible inhibitor of monoamine oxidase A (RIMA) Brofaromine, Moclobemide
Dopamine reuptake inhibitor (DARI) Amineptine, Phenmetrazine, Vanoxerine
Norepinephrine-dopamine reuptake inhibitors Bupropion, Modafinil
Norepinephrine reuptake inhibitor (NRI) or (NARI) Atomoxetine, Maprotiline, Reboxetine, Viloxazine
Serotonin-norepinephrine reuptake inhibitor (SNRI) Duloxetine, Milnacipran, Venlafaxine
Selective serotonin reuptake inhibitor (SSRI) Alaproclate, Etoperidone, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Zimelidine
Selective serotonin reuptake enhancer (SSRE) Tianeptine
Tricyclic antidepressants (TCA) Amitriptyline, Amoxapine, Butriptyline, Clomipramine, Desipramine, Dibenzepin, Dothiepin, Doxepin, Imipramine, Iprindole, Lofepramine, Melitracen, Nortriptyline, Opipramol, Protriptyline, Trimipramine
Tetracyclic antidepressants Maprotiline, Mianserin, Nefazodone, Trazodone
Noradrenergic and specific serotonergic antidepressant (NaSSA) Mirtazapine